Table 4.

Treatment administration, tolerability, and adverse events

	Arm B (4 mg)	Arm C (5.5 mg)
Ixazomib
Number of cycles	347	341
Median cycle total dose (range)	12 (2-12)	16.5 (4-16.5)
Number of patients with dose reductions, N (%)	6 (17)	15 (43)
Total number of dose reductions	7	21
Dexamethasone
Number of cycles	345	325
Median cycle total dose (range)	120 (0-240)	120 (0-160)
Number of patients with dose reductions, N (%)	8 (23)	12 (34)
Total number of dose reductions	10	16
Treatment delays
Number of patients, N (%)	9 (26)	10 (29)
Total number of delays	12	12

Frequency of AEs	Regardless of attribution	At least possibly related	Regardless of attribution	At least possibly related
Evaluable, N (%)	35 (100)	35 (100)	35 (100)	35 (100)
Grade 3+, N (%)	15 (43)	9 (26)	26 (74)	19 (54)
Grade 4+, N (%)	2 (6)	2 (6)	3 (9)	2 (6)
Grade 3+ hematologic, N (%)	6 (17)	5 (14)	15 (43)	13 (37)
Grade 4+ hematologic, N (%)	0 (0)	0 (0)	2 (6)	2 (6)
Grade 3+ nonhematologic, N (%)	10 (29)	4 (11)	18 (51)	10 (29)
Grade 4+ Nonhematologic, N (%)	2 (6)	2 (6)	1 (3)	0 (0)

There were no on-study deaths.